Paul Tudor Jones's TGTX Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 76,082 shares of TG Therapeutics, Inc. (TGTX) worth $2.75 M, representing 0.00% of the portfolio. First purchased in 2016-Q2, this long-term strategic position has been held for 38 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in TGTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2024, adding 112,661 shares. Largest reduction occurred in Q2 2024, reducing 71,404 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's TG Therapeutics (TGTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly TG Therapeutics (TGTX) Trades by Paul Tudor Jones
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2016 | +23,516 | New Buy | 23,516 | $6.08 |
| Q3 2016 | -23,516 | Sold Out | 23,516 | $0.00 |
| Q3 2017 | +17,848 | New Buy | 17,848 | $11.82 |
| Q4 2017 | -17,848 | Sold Out | 17,848 | $0.00 |
| Q1 2019 | +34,196 | New Buy | 34,196 | $8.04 |
| Q2 2019 | -34,196 | Sold Out | 34,196 | $0.00 |
| Q1 2020 | +16,160 | New Buy | 16,160 | $9.84 |
| Q2 2020 | -16,160 | Sold Out | 16,160 | $0.00 |
| Q4 2020 | +15,983 | New Buy | 15,983 | $51.99 |
| Q1 2021 | -15,983 | Sold Out | 15,983 | $0.00 |
| Q2 2021 | +19,824 | New Buy | 19,824 | $38.79 |
| Q3 2021 | -4,524 | Reduce 22.82% | 15,300 | $33.27 |
| Q4 2021 | -15,300 | Sold Out | 15,300 | $0.00 |
| Q3 2022 | +44,841 | New Buy | 44,841 | $5.91 |
| Q4 2022 | -44,841 | Sold Out | 44,841 | $0.00 |
| Q3 2023 | +94,660 | New Buy | 94,660 | $8.36 |
| Q4 2023 | -52,825 | Reduce 55.80% | 41,835 | $17.08 |
| Q1 2024 | +112,661 | Add 269.30% | 154,496 | $15.21 |
| Q2 2024 | -71,404 | Reduce 46.22% | 83,092 | $17.79 |
| Q3 2024 | -83,092 | Sold Out | 83,092 | $0.00 |
| Q1 2025 | +84,475 | New Buy | 84,475 | $39.43 |
| Q2 2025 | -84,475 | Sold Out | 84,475 | $0.00 |
| Q3 2025 | +76,082 | New Buy | 76,082 | $36.12 |
Paul Tudor Jones's TG Therapeutics Investment FAQs
Paul Tudor Jones first purchased TG Therapeutics, Inc. (TGTX) in Q2 2016, acquiring 23,516 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held TG Therapeutics, Inc. (TGTX) for 38 quarters since Q2 2016. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's largest addition to TG Therapeutics, Inc. (TGTX) was in Q1 2024, adding 154,496 shares worth $2.35 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 76,082 shares of TG Therapeutics, Inc. (TGTX), valued at approximately $2.75 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, TG Therapeutics, Inc. (TGTX) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's peak holding in TG Therapeutics, Inc. (TGTX) was 154,496 shares, as reported at the end of Q1 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.